The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II trial of induction chemotherapy with cisplatin, docetaxel, and capecitabine followed by concurrent cisplatin-radiotherapy in advanced nasopharyngeal carcinoma.
M. Yamouni
No relevant relationships to disclose
Y. Beldjilali
No relevant relationships to disclose
K. A. Benhadji
No relevant relationships to disclose
H. Khellafi
No relevant relationships to disclose
F. Betkaoui
No relevant relationships to disclose
Y. Kaid
No relevant relationships to disclose
L. Benchlef
No relevant relationships to disclose
F. Z. Daim
No relevant relationships to disclose
S. Toubal
No relevant relationships to disclose
A. Boukerche
No relevant relationships to disclose
A. Abdelaoui
No relevant relationships to disclose
L. Djellali
No relevant relationships to disclose